Molecularly targeted drugs for metastatic colorectal cancer

The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a substantial improvement in the overall survival rate. These drugs are capable of specifically targeting the inherent ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying-dong, Yang, Hua, Chen, Guo-qing, Zhang, Zhi-cao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817019/
https://www.ncbi.nlm.nih.gov/pubmed/24204124
http://dx.doi.org/10.2147/DDDT.S52485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817019/
https://www.ncbi.nlm.nih.gov/pubmed/24204124
http://dx.doi.org/10.2147/DDDT.S52485

Ejemplares similares